Asset profile
Naptumomab estafenatox
Combination
Evidence outlook · lead readout
NCT04880863 · Non-small Cell Lung Cancer
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT04880863: The study was open-label, non-randomized, and had no control group, with 38 participants receiving naptumomab estafenatox in combination with docetaxel and obinutuzumab. Its imaging-based objective response endpoint was reported, but without a comparator there was no formal treatment comparison, so the findings provide limited evidence for naptumomab estafenatox.
Also in development:HR+/HER2- Metastatic Breast Cancer · Phase 1
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.